ZA200809956B - Methods and compositions using Immunomodulatory compounds in combination therapy - Google Patents

Methods and compositions using Immunomodulatory compounds in combination therapy

Info

Publication number
ZA200809956B
ZA200809956B ZA200809956A ZA200809956A ZA200809956B ZA 200809956 B ZA200809956 B ZA 200809956B ZA 200809956 A ZA200809956 A ZA 200809956A ZA 200809956 A ZA200809956 A ZA 200809956A ZA 200809956 B ZA200809956 B ZA 200809956B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
combination therapy
immunomodulatory compounds
immunomodulatory
Prior art date
Application number
ZA200809956A
Other languages
English (en)
Inventor
Dominique Verhelle
Kyle Chan
Laura Corral
De Parseval Laure Moutouh
Helen Brady
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ZA200809956B publication Critical patent/ZA200809956B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200809956A 2006-05-26 2007-05-24 Methods and compositions using Immunomodulatory compounds in combination therapy ZA200809956B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80860206P 2006-05-26 2006-05-26

Publications (1)

Publication Number Publication Date
ZA200809956B true ZA200809956B (en) 2010-07-28

Family

ID=38606531

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809956A ZA200809956B (en) 2006-05-26 2007-05-24 Methods and compositions using Immunomodulatory compounds in combination therapy

Country Status (11)

Country Link
EP (1) EP2023912A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009538318A (cg-RX-API-DMAC7.html)
KR (1) KR20090014393A (cg-RX-API-DMAC7.html)
CN (1) CN101495111A (cg-RX-API-DMAC7.html)
AU (1) AU2007267928A1 (cg-RX-API-DMAC7.html)
CA (1) CA2652888A1 (cg-RX-API-DMAC7.html)
IL (1) IL195412A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008014912A (cg-RX-API-DMAC7.html)
RU (1) RU2426542C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007139939A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200809956B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101977603A (zh) * 2008-01-29 2011-02-16 细胞基因公司 使用免疫调节化合物来调节cd59水平的方法
WO2013142817A2 (en) * 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
EP3623011B1 (en) * 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
JP2016528297A (ja) 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
CN106455542A (zh) * 2014-03-26 2017-02-22 布里格姆及妇女医院股份有限公司 用于人造血干/祖细胞的离体扩增的组合物和方法
WO2015175916A1 (en) * 2014-05-16 2015-11-19 Celgene Corporation Methods and compositions using 4-amino-2-(2,6 dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers
EP4396331A1 (en) * 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
DK1505973T3 (da) * 2002-05-17 2010-05-31 Celgene Corp Kombinationer til behandling af multipelt myelom
KR20050057672A (ko) * 2002-10-24 2005-06-16 셀진 코포레이션 통증의 치료, 변형 및 관리를 위한 면역조절 화합물을포함하는 조성물 및 이의 사용 방법
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
BRPI0417186A (pt) * 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation

Also Published As

Publication number Publication date
AU2007267928A1 (en) 2007-12-06
WO2007139939A2 (en) 2007-12-06
KR20090014393A (ko) 2009-02-10
CN101495111A (zh) 2009-07-29
JP2009538318A (ja) 2009-11-05
EP2023912A2 (en) 2009-02-18
MX2008014912A (es) 2008-12-10
RU2426542C2 (ru) 2011-08-20
IL195412A0 (en) 2009-08-03
CA2652888A1 (en) 2007-12-06
WO2007139939A3 (en) 2008-07-03
RU2008151713A (ru) 2010-07-10

Similar Documents

Publication Publication Date Title
IL191072A0 (en) Therapeutic compositions and methods
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
EP2182922A4 (en) ANTIGEN-ADJUVANS COMPOSITIONS AND METHOD
ZA201203709B (en) Immunogenic compositions and methods
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
PL1899364T3 (pl) Kompozycje i sposoby immunomodulacji w organizmie
PL2705826T3 (pl) Kompozycja fluorku i sposoby mineralizacji zębów
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
IL198723A0 (en) Methods and compositions for therapeutic treatment
GB0721291D0 (en) Methods and compositions
IL247957A0 (en) Anti-ephrinb2 antibodies and methods of using them
IL194826A0 (en) Compositions and methods for cellular imaging and therapy
IL195412A0 (en) Methods and compositions using immunomodulatory compounds in combination therapy
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
IL196411A0 (en) Anti-cocaine compositions and treatment
GB0719526D0 (en) Compositions and methods
EP2083755A4 (en) MEDICAL KIT AND METHOD THEREFOR
EP2097085A4 (en) THERAPEUTIC MATERIALS AND METHOD
GB0617171D0 (en) Novel compositions and methods
GB0714500D0 (en) composition and treatment
GB0501348D0 (en) Compositions and methods
GB0517546D0 (en) Therapeutic methods and compositions
GB0607565D0 (en) Methods and compositions
GB0625230D0 (en) Compositions and methods
GB0616269D0 (en) Methods and compositions